C Tibaldi1, E Giovannetti2, M Tiseo3, L G Leon2, A D'Incecco4, N Loosekoot2, M Bartolotti3, R Honeywell2, F Cappuzzo4, A Ardizzoni3, G J Peters2. 1. Division of Oncology, Department of Oncology, Azienda USL-6 of Livorno, Livorno, Italy. Electronic address: tiby@katamail.com. 2. Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. 3. Division of Oncology, Department of Oncology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. 4. Division of Oncology, Department of Oncology, Azienda USL-6 of Livorno, Livorno, Italy.
Abstract
BACKGROUND: The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A>C and 435C>T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced non-small-cell lung cancer patients treated with gemcitabine-platinum-regimens. PATIENTS AND METHODS: CDA polymorphisms and activity were analysed by PCR and high-performance liquid chromatography, respectively. Univariate and multivariate analyses compared biological/clinical parameters with response, clinical benefit, time to progression (TtP) and overall survival (OS) using Pearson's χ(2) test, log-rank test and Cox proportional hazards model. RESULTS: Patients with CDA A79A/A79C genotypes had significantly longer TtP (6.0 versus 3.0 months; P = 0.001) and OS (11.0 versus 5.0 months; P = 0.001) than patients with C79C genotype. Patients harbouring CDA C435C/C435T genotypes also had a longer OS (P = 0.025), but no correlations were observed with TtP. Conversely, patients with low-CDA activity had a significantly higher response rate (37.7% versus 13.8%; P = 0.006), clinical benefit (91.8% versus 51.7%; P < 0.001), as well as longer TtP (8.0 versus 3.0 months; P < 0.001) and OS (19.0 versus 6.0 months; P < 0.001). Furthermore, enzymatic activity emerged as an independent predictor for death/progression risk at multivariate analysis. CONCLUSIONS: CDA enzymatic activity appears to be the strongest candidate biomarker of activity and efficacy of platinum-gemcitabine-based chemotherapy and should be validated in a prospective study.
BACKGROUND: The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A>C and 435C>T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced non-small-cell lung cancerpatients treated with gemcitabine-platinum-regimens. PATIENTS AND METHODS: CDA polymorphisms and activity were analysed by PCR and high-performance liquid chromatography, respectively. Univariate and multivariate analyses compared biological/clinical parameters with response, clinical benefit, time to progression (TtP) and overall survival (OS) using Pearson's χ(2) test, log-rank test and Cox proportional hazards model. RESULTS:Patients with CDA A79A/A79C genotypes had significantly longer TtP (6.0 versus 3.0 months; P = 0.001) and OS (11.0 versus 5.0 months; P = 0.001) than patients with C79C genotype. Patients harbouring CDA C435C/C435T genotypes also had a longer OS (P = 0.025), but no correlations were observed with TtP. Conversely, patients with low-CDA activity had a significantly higher response rate (37.7% versus 13.8%; P = 0.006), clinical benefit (91.8% versus 51.7%; P < 0.001), as well as longer TtP (8.0 versus 3.0 months; P < 0.001) and OS (19.0 versus 6.0 months; P < 0.001). Furthermore, enzymatic activity emerged as an independent predictor for death/progression risk at multivariate analysis. CONCLUSIONS:CDA enzymatic activity appears to be the strongest candidate biomarker of activity and efficacy of platinum-gemcitabine-based chemotherapy and should be validated in a prospective study.
Authors: Reda Z Mahfouz; Lip Seng Koh; Marissa Teo; Chit Lai Chee; Han Chong Toh; Yogen Saunthararajah Journal: Clin Cancer Res Date: 2013-05-08 Impact factor: 12.531
Authors: R Cohen; L H Preta; V Joste; E Curis; O Huillard; A Jouinot; C Narjoz; A Thomas-Schoemann; A Bellesoeur; M Tiako Meyo; J Quilichini; D Desaulle; I Nicolis; A Cessot; M Vidal; F Goldwasser; J Alexandre; B Blanchet Journal: Br J Clin Pharmacol Date: 2019-01-30 Impact factor: 4.335
Authors: Ellen J B Derissen; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen Journal: Br J Clin Pharmacol Date: 2018-04-16 Impact factor: 4.335
Authors: T E Bapiro; K K Frese; A Courtin; J L Bramhall; B Madhu; N Cook; A Neesse; J R Griffiths; D A Tuveson; D I Jodrell; F M Richards Journal: Br J Cancer Date: 2014-05-29 Impact factor: 7.640